TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least one year of age.~* Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.~* Subjects who are willing to discontinue contact lens wear for the duration of the study.~Exclusion Criteria:~* Subjects who have any uncontrolled systemic disease or debilitating disease.~* Subjects with known sensitivity or contraindications to besifloxacin, fluoroquinolones or any ingredients in study drugs.~* Subjects who are expected to require treatment with any disallowed medications.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Besifloxacin (Type: EXPERIMENTAL): 0.6% ophthalmic suspension
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Liposomal Bupivacaine for TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and older who are scheduled for a total knee arthroplasty at Northern Light Mercy Hospital~Exclusion Criteria:~* Patients under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Liposomal Bupivacaine (Type: EXPERIMENTAL): Adductor canal block using liposomal bupivacaine and conventional bupivacaine
- Standard of Care (Type: ACTIVE_COMPARATOR): Adductor canal block using conventional bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years of age~* being referred for treatment of painful shoulder (except for adhesive capsulitis)~* not having been previously treated with DF~Exclusion Criteria:~* Damaged skin and/or cutaneous lesions in the shoulder area~* History of shoulder surgery~* Vascular abnormalities~* Platelet antiaggregant therapy~* Acute inflammatory condition of the shoulder (\<1 week)~* Patients with a pending litigation or court claim

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): The intervention group was treated with a single session of DF following the procedure as described by the authors.
- Control Group (Type: PLACEBO_COMPARATOR): The control group was treated with a single placebo session of DF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~Exclusion Criteria:~* Known or suspected allergy to study product or related products.~* Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chinese outpatient of age 18 to 75~* At screening and baseline, a score of greater than 40 mm on the visual log scale of SF-MPQ~Exclusion Criteria:~* Neurologic disorders unrelated to neuropathic pain, which in the opinion of the investigator, might impair the assessment of pain~* Serum creatinine clearance greater than 60 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol: a Novel Intervention for Cannabis Use Problems?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 16 and 60 years old.~* Meet DSM-5 criteria for moderate cannabis use disorder (≥4 DSM-5 criteria)~* Express desire to quit using cannabis within the next four weeks,~* Have ≥1 previous failed quit attempt.~* Smoke tobacco with cannabis,~* Test positive for recent cannabis use according to urine analysis,~* Vital signs within healthy limits and have capacity to give consent~Exclusion Criteria:~* Not willing to use effective contraception from when consent is taken to 6 weeks after treatment has stopped~* Positive pregnancy test or breastfeeding~* Allergies to the Investigational Medicinal Product (IMP) or placebo and its excipients~* \>twice/month use of other illicit drugs~* Outside normal Body Mass Index (BMI)~* A physical health problem deemed clinically significant~* The use of current prescribed psychotropic drugs~* Current or prior self-reported diagnosis of a psychotic disorder~* Non-English speakers due to verbal assessments.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Cannabidiol 200mg Oral (Type: EXPERIMENTAL): None
- Cannabidiol 400mg Oral (Type: EXPERIMENTAL): None
- Cannabidiol 800mg Oral (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients living independently in residential homes for the elderly or day patients)~* have mild to moderate dementia, as evidenced by a Mini-Mental Status Examination (MMSE) score of 11 - 24 and a score of at least 12 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog)~* history of at least a 6 months of gradual and progressive cognitive decline~* have a consistent informant to accompany the patient on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* dementia caused by small strokes or cerebrovascular disease~* cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation or a brain tumor~* having epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney, or lung disorders, or heart disease~* Females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients, of age 18 - 54 years~* Patients diagnosed with stage 1 or stage 2 essential hypertension~* Normal physical examination findings and electrocardiogram (ECG) results or abnormal findings judged by the Investigator to be not clinically significant~Exclusion Criteria:~* Secondary hypertension or severe hypertension~* History of Type 1 diabetes mellitus~* A medical contraindication to discontinuing a current antihypertensive therapy~* Clinically significant respiratory disease that prohibit use of a beta blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
- 2 (Type: PLACEBO_COMPARATOR): Dose-matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine in Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 - 60 aged patients~* orthopedic operation undergoing spinal anesthesia~Exclusion Criteria:~* more than American society of anesthesiologists classification 3~* hypertension~* diabetes mellitus~* heart disease (bradycardia, atrioventricular block)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
- Dexmedetomidine with heavy bupivacaine (Type: ACTIVE_COMPARATOR): IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient will be implanted with a Medtronic Conexus-enabled Cardiac Resynchronization Therapy Defibrillator (CRT-D) or Implantable Cardioverter-Defibrillator (DR-ICD) device.~Exclusion Criteria:~* Patient has permanent rapid beats in the upper chamber of the heart (Atrial Fibrillation) - (constant atrial fibrillation in which pharmacological therapy or cardioversion failed or not attempted).~* Patient plans to be on chronic warfarin therapy post-implant and is no longer receiving therapies to attempt to control the rhythm of the beats in their atrium.~* Patient has a previous ICD, CRT-D, Implantable Pulse Generator (IPG) or Cardiac Resynchronization Therapy Pacemaker (CRT-P).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remote Arm (Type: EXPERIMENTAL): Remote Management
- In-office Arm (Type: ACTIVE_COMPARATOR): In-Office Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary disease is acute leukemia/MDS/CML~* Receiving allo-HSCT~Exclusion Criteria:~* cardiac dysfunction (particularly congestive heart failure)~* hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase\> 2 times the upper limit of normal)~* renal dysfunction (creatinine clearance rate \< 30 mL/min)~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- MSD group (Type: EXPERIMENTAL): The patients will received HSCT from MSD.
- MUD group (Type: EXPERIMENTAL): The patients will received HSCT from MUD.
- HRD group (Type: EXPERIMENTAL): The patients will received HSCT from HRD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of B-cell chronic lymphocytic leukemia~  * Rai stage 0-II (Binet stage A) disease~* Meets 1 of the following criteria:~  * High-risk disease, as defined by the following:~    * Serum thymidine kinase level \> 7.0 U/L~   * Elevated β2-microglobulin level~   * Presence of non-nodular bone marrow infiltration~   * Short lymphocyte doubling time~ * Low-risk disease~    * Meets none of the criteria (as listed above) for high-risk disease~PATIENT CHARACTERISTICS:~Performance status~* Not specified~Life expectancy~* More than 6 months~Hematopoietic~* No autoimmune hemolytic anemia~* No thrombocytopenia~Hepatic~* Not specified~Renal~* Not specified~Other~* No severe organ dysfunction~* No other prior or concurrent malignancy~PRIOR CONCURRENT THERAPY:~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine (Type: EXPERIMENTAL): None
- watch & wait (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~type 2 diabetes mellitus -age between 40 and 75 years -well controlled HbA1c (\< 7.5%) -chronic renal failure (creatinin clearance between 70 and 30 mL/(min x 1.73 m²) according to the Cockroft equation) -proteinuria \> 300 mg / 24 hours~Exclusion Criteria:~type 1 diabetes -poorly controlled type 2 diabetes (HbA1c \> 7.5%) or unstable blood glucose during the day (capillary blood glucose self monitoring) -elevation of ALT, AST or GGT more than 2.5 fold the upper normal value -CHF (more than grade 1 of NYHA) -uncontrolled hypertension -malignant tumorous disorder -hyper- or hypothyroidism -pregnant women -nursing women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rosiglitazone (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18-45 years~* BMI approximately ≥ 25 and \< 35~* insulin approximately ≥ 15 µU/ml or triglyceride approximately ≥ 130 mg/dl~Exclusion Criteria:~* Any DSM-IV Axis I diagnosis~* prisoners~* any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection)~* taking prescription medications~* non-sedentary lifestyle with \> 3 hours of exercise per week

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- olanzapine (Type: ACTIVE_COMPARATOR): olanzapine injection in healthy control
- ziprasidone (Type: ACTIVE_COMPARATOR): ziprasidone injection in healthy control
- saline (Type: PLACEBO_COMPARATOR): saline injection in healthy control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Outpatient at least 12 years of age~* Both genders; females of child bearing potential must be willing to use approved birth control method~* Pre-bronchodilator FEV1 of 40-90% predicted~* Reversibility FEV1 of at least 12% and 200mLs~* Current asthma therapy that includes an inhaled corticosteroid for at least 4 weeks prior to first visit~Exclusion Criteria:~* History of life threatening asthma~* Respiratory infection or candidiasis~* Asthma exacerbation within 6 months prior to first visit~* Concurrent respiratory disease or other disease that would confound study participation or affect subject safety~* Allergies to study drugs, study drug excipients, medications related to study drugs~* Taking another investigational medication or medication prohibited for use during this study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate OD and Placebo BID (Type: EXPERIMENTAL): Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
- Fluticasone Propionate BID and Placebo OD (Type: ACTIVE_COMPARATOR): Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
- Placebo only BID (Type: PLACEBO_COMPARATOR): Placebo inhalation powder twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~  * Patients with advanced or metastatic renal cell carcinoma, histologically confirmed, with at least one radiological response assessment~ * Patients who had received Axitinib treatment in second or further line with a PFS ≥9 months or DP (disease progression) at the first tumor assessment.~ * For the patients alive at the moment of the inclusion, patients must have a signed informed consent document~Exclusion Criteria:~* Axitinib received out of the approved indication Patients who do not meet any of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a documented history of permanent AF (cardioversion failure) as defined by the ACC/AHA/ESC Guidelines.~2. Concomitant indication (other than AF) for open-heart surgery for one or more of the following:~   * Mitral valve repair or replacement~  * Aortic valve repair or replacement~  * Tricuspid valve repair or replacement~  * Atrial septal defect (ASD) repair~  * Patent foramen ovale (PFO) closure~  * Coronary artery bypass procedures~3. Greater than or equal to 18 years of age~4. Able and willing to comply with study requirements by signing a consent form~5. Must be able to take the anticoagulant warfarin (Coumadin)~Exclusion Criteria:~1. Wolff-Parkinson-White syndrome~2. NYHA Class = IV~3. Left ventricular ejection fraction ≤ 30%~4. Need for emergent cardiac surgery (i.e. cardiogenic shock)~5. Previous ablation for atrial fibrillation, AV-nodal ablation, or surgical Maze procedure~6. Contraindication for anticoagulation therapy~7. Left atrial diameter \> 7.0 cm~8. Preoperative need for an intra-aortic balloon pump or intravenous inotropes~9. Renal failure requiring dialysis or hepatic failure~10. Life expectancy of less than one year~11. Pregnancy or desire to be pregnant within 12 months of the study treatment.~12. Current diagnosis of active systemic infection~13. Documented MI 6 weeks prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete